Navigation Links
Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome
Date:7/22/2014

LOS ANGELES, July 22, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ Therapy for the treatment of neurological and neuropsychiatric disorders, today announced that enrollment has begun in a pediatric open label study of external trigeminal nerve stimulation (eTNS) as adjunctive therapy for the treatment of Lennox-Gastaut Syndrome (LGS).

The trial is being conducted at the Olive View-UCLA Medical Center in Sylmar, California, and led by Professor D. Alan Shewmon, M.D., Chief of Neurology at Olive View and Vice Chair of Neurology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).  The U.S. National Institutes of Health (NIH) has provided grant funding to NeuroSigma to support this open label trial of eTNS in children with LGS, ages 8 to 18.  The children in this study will use the eTNS therapy each night at home while remaining on their antiepileptic medications.  An earlier Phase II clinical trial of eTNS therapy for the treatment of drug-resistant epilepsy (DRE) in adults found significant improvements in the frequency of seizures with 18 weeks of nightly eTNS therapy. Dr. Shewmon does not have an affiliation with NeuroSigma.

LGS is a catastrophic form of childhood epilepsy characterized by three key features: multiple types of seizures, particularly "tonic" (stiffening) and "atonic" (drop) seizures; impaired intellectual development; and specific abnormalities on the electroencephalogram (brain wave test). Seizures usually develop between 3 and 5 years of age.  LGS is often difficult to control with ordinary antiepileptic drug treatments.  The Epilepsy Foundation reports that LGS accounts for 2-5% of chi
'/>"/>

SOURCE NeuroSigma
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Seres Health Completes Enrollment in a Clinical Study for SER-109 in Recurrent Clostridium difficile Infection and Announces Positive Preliminary Data
2. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
3. Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
4. Irvine Center for Clinical Research Announces Open Enrollment for New Low Testosterone Study
5. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
6. Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinsons Disease
7. AtheroMed Announces Completion of Patient Enrollment in the EASE Study Evaluating the Phoenix Atherectomy System in Treating PAD
8. Successful Clinical Trials, Recognitions, Enrollment in Studies, Product Launches, and Strategic Announcements - Research Report on Boston Scientific, Gilead, Abbott, Actavis, and Covidien
9. Adynxx Completes Patient Enrollment in Phase 2 Clinical Study of Lead Therapeutic for Prevention of Pain, AYX1
10. SanBio Announces The Completion Of Enrollment Of Its Clinical Trial Of Cell Therapy For Chronic Stroke Deficits
11. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014  Medical Diagnostic Laboratories, L.L.C., (MDL), ... high complexity, state-of-the-art, automated DNA-based molecular analyses, ... Cystic Fibrosis Testing which utilizes cutting edge ... Cystic fibrosis (CF), or mucoviscidosis, ... affects the respiratory, gastrointestinal and reproductive systems. ...
(Date:10/22/2014)... Oct. 22, 2014  Rescheduling of hydrocodone combination ... the pain market, according to a new primary ... firm providing market research and consultation exclusively in ... - http://photos.prnewswire.com/prnh/20141021/153440 In ... hydrocodone combination products from Schedule III to Schedule ...
(Date:10/22/2014)... -- Investor-Edge has initiated coverage on the ... ), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ), ... Pharmaceuticals Inc. (NASDAQ: IDRA ), and Merrimack ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,419.48, up 2.40%, the Dow Jones Industrial ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5
(Date:10/25/2014)... 2014 TASC (Total Administrative Services ... benefits account management services, announces the release of ... on taxes, reduce administrative workload, and lessen liability. ... and the efficient handling of complex, time-sensitive, and ... best meets their goals and objectives. The four ...
(Date:10/25/2014)... 2014 The federal judge overseeing ... ) filed against Boston Scientific Corp. in the ... Southern District of West Virginia has denied a ... in a group of cases filed on behalf ... October 21st, U.S. District Judge Joseph R. Goodwin ...
(Date:10/25/2014)... (HealthDay News) -- Not getting the right amount of ... new study suggests. Those who sleep less or ... night may be more prone to developing the chronic ... The study authors concluded that duration and quality of ... with inflammatory bowel diseases. "Both short and long ...
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- October,s shorter, darker days ... affective disorder, according to an expert. People ... feel overly tired, lack motivation and even have trouble ... lead to suicide, said Dr. Angelos Halaris, a professor ... Loyola University Chicago Stitch School of Medicine. "Seasonal ...
(Date:10/22/2014)... Isabel Healthcare will participate ... (ASAHP) Conference on October 22-24 in Las Vegas, NV. ... a panel discussion on Technology in Health Professions Education ... a diagnostic decision support tool and clinical education platform ... students and clinical learners. The Isabel tools help clinicians ...
Breaking Medicine News(10 mins):Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2
... ... ... Dozier Internet Law, P.C. has filed a lawsuit (Case No. CGC-10-499227) on behalf of ... San Francisco, against Yelp! Inc. The lawsuit alleges that Yelp! has been operating an ...
... Abstract 35P: Markers for risk of pregnancy-associated breast ... child-birth to the third and fourth decades, the ... rise. This paper suggests that identification of p53 ... outbreak or early detection of pregnancy-associated breast cancer. ...
... as epigenetic modifications, regulate the activity of many ... often inactivates important cellular growth brakes. Therefore, this ... major cause of uncontrolled division of cancer cells. ... methylation. Unlike changes in the blueprint ...
... one wants antibiotic residues in their milk. But antibiotics are ... conducted nowadays take hours to produce a result and do ... can now be closed, thanks to a fully automated minilab ... LMU Muenchen and gwk Praezisionstechnik GmbH. Even at ...
... had previous sprain, study says , FRIDAY, May 7 ... in female high school volleyball players, a new study ... players (59.3 percent female, 40.7 percent male) who wore ... and non-rigid) for an entire season and 42 who ...
... contraceptives altered the social and sexual landscape in ways expected ... millions of women have taken it at some point in ... have been arrested for it and it,s still one of ... it,s simply known as "the Pill." , On May 9, ...
Cached Medicine News:Health News:Yelp! Sued Over Alleged Protection Racket 2Health News:Interesting stories at the IMPAKT Breast Cancer Conference 2Health News:Interesting stories at the IMPAKT Breast Cancer Conference 3Health News:Fatty acid to enhance anticancer drug 2Health News:Minilab can quickly identify antibiotic residues in milk, before it leaves the barn 2Health News:Minilab can quickly identify antibiotic residues in milk, before it leaves the barn 3Health News:Ankle Braces May Protect Girl Volleyball Players 2Health News:The Pill Turns 50 2Health News:The Pill Turns 50 3Health News:The Pill Turns 50 4Health News:The Pill Turns 50 5
... Ureteral Stents have all the advantages ... addition, a unique 360 degree kidney ... placement in the renal pelvis or ... remarkably comfortable stent, ideal for use ...
All the advantages of Dr. Roy P. Finney's classic stent design with an open tip....
This EIA microplate opens new perspectives in the direct detection of Chlamydia. The choice of microplate immunoenzymatic technology and the use of a monoclonal antibody result in a combination of c...
Inquire...
Medicine Products: